A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood

NCT07753174 | Recruiting

• 2 other identifiers: 20833legacy-20833
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 1

Brief Summary

This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing. The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.

Conditions

DHA and EPA Blood Levels; Omega-3 Deficiency; Cardiovascular Health; Cognitive Health

Outcome Measures

Primary Outcomes (2)

• Change in DHA levels in the blood

  Change from Baseline in DHA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center

  Baseline and Week 12

• Change in EPA levels in the blood

  Change from Baseline in EPA blood concentration as assessed by blood biomarker testing (test code 92701) at Quest Diagnostics Center

  Baseline and Week 12

Secondary Outcomes (4)

• Change in self-reported cognitive performance

  Baseline, Week 4, Week 8, and Week 12

• Change in self-reported gastrointestinal symptoms

  Baseline, Week 4, Week 8, and Week 12

• Change in self-reported overall health and well-being

  Baseline, Week 4, Week 8, and Week 12

• Participant experience with consumption of the test product

  Baseline, Week 4, Week 8, and Week 12

Study Arms (1)

Omega Active Supplement

EXPERIMENTAL

Dietary Supplement: Omega Active Supplement

Interventions

Omega Active Supplement DIETARY_SUPPLEMENT

All participants receive one dose (two capsules) of the Omega Active omega-3 supplement daily for 12 weeks.

Omega Active Supplement

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be male or female.
• Be aged 18-65.
• Anyone in good general health.
• Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
• Must not have taken fish oil or plant-based omega oil supplements in the past eight weeks.
• Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.
• Resides in the United States.

You may not qualify if:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
• Anyone on anticoagulants or antiplatelet therapy.
• Anyone with a bleeding disorder.
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
• Anyone unwilling to follow the study protocol.
• Anyone who does not consume any specific dietary ingredients for any reason.
• Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.

Sponsors & Collaborators

• Revive Active: lead
• Citruslabs: collaborator

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89101, United States

RECRUITING

Central Study Contacts

Patrick Renner

CONTACT

4242450284

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 3, 2026
• First Posted: August 7, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: August 7, 2026

Record last verified: 2026-08

Locations

US (1)